Research Misconduct – A Year in Review

SRA, October 2019
Debbie Parrish
Parrish Law Offices
Research Misconduct

- Federal Agency Action
- Litigation and Criminal Prosecution
- Institutional Payback
- Environmental Factors
Agency Action - ORI and NSF

- ORI – Staffing – new interim director – Lis Handley
  - Scott Moore leaves after 3 yrs
  - New DIO – Runko (but Kriepke)

- Cases – 4 so far
  - Agarwal – admission, 1 yr supervision, NCI made up 60 exp.
  - Cruikshank – 5 yr exclusion, images in paper, 2 grants and seminar, retired from BU
  - Fox – admission – ms and grant application, 1 yr supervision, U of WA
  - Rajendra – admission, Colorado PhD student, falfied data in 9 papers and thesis, 3 yr exclusion
NSF Cases

- 2018 on track – 14 findings
- PI who falsified data debarred for 5 years
- PI who plagiarized proposal debarred for 1 yr
- Grad student who falsified data – proposed 1 yr debarment
- NSF program officer who plagiarized, proposed 2 yr debarment
- PI who falsified letters of support and plagiarized, 3 yr certification and 1 yr not a reviewer
- PI who plagiarized in proposal, 1 yr not a reviewer
Litigation

- Duke – Qui tam – settled for $112.5 Million

- Croce – libel, slander, EOC, retraction
  - Sued NYT – lost in 6the cct.
  - 9 papers retracted, many EOCs
  - Sued to get position back – denied TRO

FTC won $50M fine against predatory publisher
Other Interesting cases

- Shi and Zhang – UK, JBC 3 retractions, Fed. ORI has
- Boghossian – Portland State, published fake gender studies, dog-on-dog, revealed to WSJ
- Armstrong – Columbia – plagiarism and fake sources
- Wansink – 18 articles retracted (JAMA-6)
  - Cornell – larger plates lead to over-eating, Joy of Cooking, grocery shopping hungry, bad popcorn, p-hacking, power peas
Institutional Payback

- Duke - $112 M

- Jamal – Canadian researcher who paid back $260k + $5,500 in court costs and banned
FDA and Misconduct

- FDA had proposed own misconduct reporting ruling in Feb. 2010
- Oct. 17, 2018 withdrew proposed rule
- Aug. 6, 2019, FDA declares Novartis’ application for new drug included falsified pre-clinical data
What Else?

- Retractions for VCU taking too long
- World Conference on Research Integrity in Hong Kong 2019
- Sweden set up national body in wake of Macchiarini
- UT can’t summarily revoke degree for misconduct
- Macau bill for up to 2 years in prison for plagiarism
- German politician loses degree
- VP of Karolinska out for misconduct